—
C+
C+ The full Closelook — membership. Open the C+ overview

Grifols S.A. (GRF.MC) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Grifols S.A.

GRF.MC in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Grifols researches, produces and sells medicines made from human plasma, along with diagnostic testing equipment and hospital supplies. It runs through segments covering biopharma, diagnostics, bio supplies for other manufacturers, and hospital and laboratory services. Customers include hospitals, biotech firms and life-science researchers across the United States, Canada, Spain and other markets. It is based in Barcelona, Spain.
Where it sits in the stack
Grifols has no seat in our index and does not sit inside the AI build-out stack; it belongs to our Healthcare sector, in the Drug Manufacturers - General industry group.
Who it is priced against
The diary has not built a peer group for it; the comparison the market draws is with CSL, another large plasma-derived medicine maker.
Why Closelook tracks it
It carries a Closelook score, but with only one module scored the read is still being built; it holds no index seat and has not yet appeared in a diary edition or quote.
What the diary watches
The diary watches whether the shares stabilise against their recent slide below the 50- and 200-day averages, or move back toward the high they reached earlier in the year.

Grifols S.A. (GRF.MC) trades on the MC exchange in Spain, classified under Healthcare.

The Closelook company score reads 48/100 composite (momentum 45, quality 43, valuation 79) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for GRF.MC, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against GRF.MC on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 0.70%, annual · buybacks 129 m EUR in FY2025

Dividends and capital return

What GRF.MC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.0667 EUR per share · a 0.70% yield on the 2026-09-18 close 1 distribution, paid once a year 2026-09-18
  • Change on the year −45.1% against the prior twelve months prior twelve months 0.12 EUR per share
  • Last distribution 0.0667 EUR per share as the price series records it, within days of the ex-date 2026-06-30
  • By calendar year 2025: 0.12 EUR (partial) · 2026: 0.0667 EUR to date first distribution recorded in the three-year window: 2025-08-11
  • Dividends paid, FY2025 128 m EUR 12% of earnings
  • Buybacks, FY2025 129 m EUR 2.0% of today's market value
  • Share count +1.1% in FY2025
  • Capital returned 257 m EUR · 41% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in Europe: +3.0% week · −4.5% month · −2.1% quarter · −5.0% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Grifols S.A. (GRF.MC)?

Grifols S.A. trades as GRF.MC on the MC exchange (Spain) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is GRF.MC in a Closelook index?

Not currently — Grifols S.A. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Grifols S.A.'s Closelook composite score?

48 out of 100, with momentum 45, quality 43 and valuation 79 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does GRF.MC trade against its moving averages?

Mixed moving-average stack: Trades -2.8% vs the 50-day and -2.7% vs the 200-day average, 25.3% below the 52-week high and +14% off the 52-week low; a golden cross printed 1 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Grifols S.A. do?

Grifols researches, produces and sells medicines made from human plasma, along with diagnostic testing equipment and hospital supplies. It runs through segments covering biopharma, diagnostics, bio supplies for other manufacturers, and hospital and laboratory services. Customers include hospitals, biotech firms and life-science researchers across the United States, Canada, Spain and other markets. The diary has not built a peer group for it; the comparison the market draws is with CSL, another large plasma-derived medicine maker.

Where does Grifols S.A. sit in the AI build-out?

Grifols has no seat in our index and does not sit inside the AI build-out stack; it belongs to our Healthcare sector, in the Drug Manufacturers - General industry group. It carries a Closelook score, but with only one module scored the read is still being built; it holds no index seat and has not yet appeared in a diary edition or quote.

Does Grifols S.A. pay a dividend?

Grifols S.A. has paid 0.0667 EUR per share over the last twelve months, paid once a year, a trailing yield of 0.70% on the 2026-09-18 close; the last distribution recorded in the price series was 0.0667 EUR on 2026-06-30. In fiscal 2025 the company paid 128 m EUR in dividends and bought back 129 m EUR of its own shares, 41% of that year’s free cash flow. The share count rose 1.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for GRF.MC, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.